Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADORA1 antisense RNA 2 (ADORA1-AS2) does not appear in main biomedical databases as a well-characterized or established molecular target. There is strong evidence that the name refers to a predicted or annotated non-coding RNA transcript, specifically an antisense long non-coding RNA (lncRNA) transcribed from the opposite strand of the ADORA1 (Adenosine A1 receptor) gene locus. The gene ADORA1 is a well-characterized G protein-coupled receptor involved in neurotransmission and immunomodulation. "ADORA1 antisense RNA 2" refers to an antisense non-coding RNA overlapping or nearby the ADORA1 locus. There is no robust evidence that it encodes a protein or acts as a canonical drug target such as a receptor, enzyme, or transporter. Most mentions of antisense transcripts like this refer to NR_ or XR_ sequence predictions in genome annotations and are not validated as functional therapeutic targets nor as having known interacting drugs. No actionable drugs, biomarkers, or mechanism of action are described for "ADORA1-AS2" in the literature. Most therapeutic or biomarker research focuses on the protein ADORA1, not the antisense RNA. ADORA1 antisense RNA 2 (ADORA1-AS2) is an annotated long non-coding RNA (lncRNA) transcript that is transcribed from the antisense strand relative to the ADORA1 gene locus. There is no strong evidence of an established biological function, protein product, or direct role in disease for ADORA1-AS2. It is not considered a canonical therapeutic target. Research in the ADORA1 genomic region primarily centers on the protein-coding ADORA1 gene, a major adenosine receptor; antisense non-coding RNAs like ADORA1-AS2 are annotated in genome projects but have not been experimentally characterized as druggable targets or biomarkers. In summary, ADORA1-AS2 is not a canonical therapeutic target. The entity is correctly named but not considered a target. Information is lacking regarding biological role, clinical utility, and druggability. Focus therapeutic and druggability queries on the ADORA1 protein rather than the antisense RNA.
None described
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADORA1 antisense RNA 2 (ADORA1-AS2).